What Medications Work Like Ozempic? A Science-Based Guide to GLP-1 Receptor Agonists

Ozempic has become shorthand for an entire revolution in obesity medicine — but semaglutide is just one player in a rapidly expanding field. If you’re researching GLP-1 receptor agonists, either because you’re already on one or you’re trying to understand your options, the landscape is broader and more nuanced than most mainstream coverage suggests. A 2022 systematic review in the Journal of the ASEAN Federation of Endocrine Societies confirmed that subcutaneous semaglutide produces an average weight reduction of nearly 12% from baseline compared to placebo — a landmark finding that helped ignite global interest in this drug class. But semaglutide is neither the first nor the last word in GLP-1 therapy.

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a naturally occurring gut hormone that signals satiety to the brain, slows gastric emptying, and modulates insulin secretion in a glucose-dependent manner. The result is reduced appetite, improved blood sugar regulation, and — when used consistently — meaningful, sustained fat loss. What separates the medications in this class from one another comes down to molecular structure, dosing frequency, delivery method, and potency. Understanding those differences matters whether you’re a clinician, a patient weighing your choices, or a man who simply wants to know what the science actually says.

The Established Players: Liraglutide and Semaglutide

Before semaglutide dominated headlines, liraglutide — sold as Victoza for diabetes and Saxenda for weight management — was the gold standard injectable GLP-1 therapy. It requires daily subcutaneous injections, which immediately distinguishes it from semaglutide’s once-weekly dosing. That difference in convenience proved clinically significant. The STEP 8 randomized clinical trial published in JAMA put both drugs head-to-head in 338 adults with overweight or obesity and no diabetes, running for 68 weeks. Semaglutide produced a mean weight loss of 15.8% from baseline. Liraglutide produced 6.4%. That’s not a marginal difference — it’s a near 10-percentage-point gap, and the odds of achieving clinically meaningful thresholds like 15% or 20% body weight loss were dramatically higher with semaglutide across every benchmark measured.

Just as telling: dropout rates. Only 13.5% of semaglutide participants discontinued treatment, compared to 27.6% in the liraglutide group — suggesting that tolerability and dosing convenience both play real roles in whether patients actually stick with therapy long enough to see results. Gastrointestinal side effects, primarily nausea and vomiting, were similarly common in both groups (around 82–84%), which underscores that GI burden is a class-wide characteristic, not unique to any single drug. The practical implication is straightforward: if you or someone you know is weighing liraglutide against semaglutide and efficacy is the primary concern, the clinical evidence strongly favors the latter — though liraglutide remains a legitimate option where cost, access, or individual tolerance is a factor.

Semaglutide itself also exists in two branded forms worth distinguishing. Ozempic is the 0.5–2 mg weekly injectable approved for type 2 diabetes. Wegovy is the 2.4 mg weekly formulation approved specifically for chronic weight management. Oral semaglutide (Rybelsus) is FDA-approved at lower doses for diabetes, and a 2025 systematic review in Pharmacological Reviews noted that oral semaglutide at 50 mg is the only emerging formulation to have completed a phase 3 obesity trial — a signal that the next generation of GLP-1 options will eventually include high-efficacy pills alongside injectables.

Tirzepatide and the Dual-Agonist Advantage

If semaglutide raised the ceiling on what weight loss medication could achieve, tirzepatide — marketed as Mounjaro for diabetes and Zepbound for obesity — may have raised it again. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor simultaneously. GIP amplifies insulin response and may enhance GLP-1’s appetite-suppressing effects in ways that a single receptor agonist cannot fully replicate. Clinical trial data has shown tirzepatide achieving weight reductions exceeding 20% in some populations — results that begin to approach what was previously only possible through bariatric surgery.

A 2025 real-world evidence review in Diabetes, Obesity & Metabolism evaluated how liraglutide, semaglutide, and tirzepatide perform outside of controlled trial conditions. The findings were nuanced but instructive. Real-world weight loss tends to be lower than in clinical trials — likely because patients use lower doses, adhere less strictly, and discontinue at high rates (20–50% within the first year). But among highly adherent patients, real-world outcomes closely mirror trial results. This matters for men considering or currently on these medications: how you use the drug — the dose you reach, your consistency, your dietary behavior alongside it — has an enormous impact on what you actually get out of it.

The same review flagged gastrointestinal side effects as the primary driver of early discontinuation across all three medications. Nausea, vomiting, and diarrhea are real and common, particularly during dose escalation. Slow titration protocols exist precisely to manage this, and most side effects diminish over time. Critically, real-world data found no clear increase in serious adverse events like pancreatitis, pancreatic cancer, or thyroid disorders — concerns that circulate widely online but have not been substantiated in large-scale observational populations.

What’s Coming Next in GLP-1 Therapy

The pipeline beyond tirzepatide is substantial and accelerating. The 2025 Pharmacological Reviews systematic review catalogued 53 phase 2 and phase 3 trials covering 36 emerging antiobesity agents. Several are worth knowing about. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, with phase 2 data showing weight losses as high as 24.2% — numbers that, if confirmed in phase 3, would represent a step change in what pharmacotherapy can deliver. CagriSema combines semaglutide with cagrilintide, an amylin analog, working on complementary neurological pathways to suppress appetite. Orforglipron is an oral non-peptide GLP-1 receptor agonist in late-stage trials that could eventually eliminate the need for injections entirely at meaningful efficacy levels.

The pattern here is deliberate: the drug class is moving toward more receptor targets, more convenient delivery, and greater potency. The weight loss thresholds being reported in phase 2 trials — often exceeding 15% and in some cases approaching 25% — represent a meaningful shift in what medicine can realistically offer patients with obesity. That said, data on cardiovascular outcomes, long-term safety, mortality, and cost-effectiveness for these newer agents is still sparse. The science is evolving faster than the evidence base for long-term use, which is a legitimate reason for measured optimism rather than uncritical enthusiasm.

It’s also worth grounding all of this in a foundational reality: these medications work best in men who are also optimizing diet, resistance training, sleep, and stress management. The STEP 3 trial demonstrated that semaglutide combined with intensive behavioral therapy and a low-calorie diet produced 16% average weight loss — a result that reflects not just the drug’s pharmacology but the compounding effect of lifestyle aligned with the medication’s mechanism. No GLP-1 agonist overrides poor sleep, sedentary behavior, or chronic overfeeding indefinitely. The men who get the most out of these medications are the ones who treat them as a powerful adjunct to disciplined lifestyle habits, not a replacement for them.

The Takeaway

The medications that work like Ozempic — liraglutide, tirzepatide, and the growing pipeline of dual and triple agonists — all operate on the same fundamental biology: amplifying your body’s natural satiety signaling to reduce appetite and improve metabolic function. What separates them is how effectively and how conveniently they do it. Semaglutide currently leads the established field on efficacy for most men. Tirzepatide pushes that ceiling higher. The next generation of agents may push it higher still. But across every drug in this class, the data is consistent: real-world adherence, dose optimization, and lifestyle behavior remain the variables most in your control — and most predictive of your results.